MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/dddt.s568452

Медицинская библиотека · Drug design, development and therapy · 2026

Remimazolam and Postoperative Delirium in Patients with Hyperlipidemia: A Retrospective Cohort Study with Target Trial Emulation Analysis.

Tang Yuling, Long Menghong, Gao Yuhang, Kowark Ana, Coburn Mark, Wan Hengjun, Li Yiyun, Duan Xiaoxia

СтатьяПеревод в очереди

Аннотация

PURPOSE: Hyperlipidemia increases postoperative delirium (POD) risk via neuroinflammation; however, effective pharmacological interventions to mitigate POD in this population remain limited. Remimazolam has been reported to reduce perioperative stress and modulate neuroinflammatory responses. We investigated the effect of remimazolam on POD incidence in surgical patients with hyperlipidemia.

PATIENTS AND

METHODS

In this retrospective cohort study, we enrolled 1123 patients with hyperlipidemia who underwent surgery under general anesthesia with or without remimazolam at a single institution. The primary outcome measure was POD incidence within 3 days postoperatively. To assess the impact of remimazolam on POD, a target trial emulation framework was applied to enhance control of confounders and strengthen causal inference. We additionally investigated the dose-response relationship between remimazolam exposure and POD.

RESULTS

POD incidence in the remimazolam group was 13.8%, which was 7.2% lower than that in the non-remimazolam group (P<0.01). Additionally, delirium severity (median score: 9 vs 10, P<0.01) and cognitive impairment incidence at 6 months postoperatively (4.4% vs 8.3%, P<0.05) were lower in the remimazolam group. The target trial emulation further confirmed the protective effects of remimazolam on POD (adjusted risk difference [aRD]: -5.3%, P=0.016), delirium severity (aRD: -2.238, P<0.001), and cognitive dysfunction incidence at 6 months postoperatively (aRD: -3.97%, P=0.019). Dose-response analysis showed a significant reduction in POD incidence when the total remimazolam dose was ≥10.29 mg or the maintenance rate was ≥0.51 mg kg-1 h-1.

CONCLUSION

Remimazolam significantly reduced POD incidence and severity in patients with hyperlipidemia and improved cognitive function at 6 months postoperatively. However, prospective studies are needed to confirm these findings.

Для цитирования: Tang Yuling, Long Menghong, Gao Yuhang, Kowark Ana, Coburn Mark, Wan Hengjun, Li Yiyun, Duan Xiaoxia. Remimazolam and Postoperative Delirium in Patients with Hyperlipidemia: A Retrospective Cohort Study with Target Trial Emulation Analysis.. Drug design, development and therapy. 2026. DOI: 10.2147/dddt.s568452.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.